Loading...
NPI 1073626388 · Great Neck, NY · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Vincent Deramo is a ophthalmology physician provider located in Great Neck, New York. This profile covers 28 Medicare and 4 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Vincent Deramo |
| Address | 600 Northern Blvd |
| City | Great Neck |
| State | NY |
| ZIP | 11021 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | August 17, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $4M |
| Medicaid | $15.1K |
This provider’s Medicare portfolio is heavily weighted toward intravitreal biologic injections: J0178 (aflibercept) generates $2.1M and accounts for 52.9% of Medicare revenue, and the precomputed top-three Medicare codes together account for 71.5% of total Medicare revenue. The specific high-dollar drug mix (aflibercept, faricimab, ranibizumab biosimilar) indicates the practice is oriented around medical retina care and frequent outpatient injection therapy rather than primarily refractive or routine eye care.
Medicare competitive standing is concentrated and in some cases well above peers: J0178 ranks #175 of 3204 providers nationally (95th percentile) and is described as notably above typical national volume, while J2777 and Q5128 rank in the 68th percentile range (typical, unremarkable volume). Additionally, the provider reports 3.4K Medicare claims for 92134 and ranks #253 of 26868 providers nationally (99th percentile), an extreme outlier that signals an unusually large retinal imaging workload compared with national peers.
Revenue concentration creates a business profile that centers on high-volume drug administration and retinal diagnostics. On Medicare the top three drug codes drive 71.5% of revenue and on Medicaid the precomputed top-three codes account for 99.4% of Medicaid revenue, showing that a small set of services (largely intravitreal injections and retinal imaging) account for nearly all billings to both payers.
Payer mix is effectively Medicare-dominant: lifetime Medicare revenue is $4M compared with lifetime Medicaid revenue of $15.1K, so the practice’s financial scale and clinical activity are overwhelmingly tied to Medicare beneficiaries. Medicaid activity exists but is negligible in dollar terms and concentrated in a small number of codes, so Medicaid reimbursement will not meaningfully drive overall revenue.
Medicaid billing is narrowly concentrated and modest in scale: 92134 contributes $8K (52.2% of the provider’s Medicaid revenue) and 67028 contributes $7.1K (46.1% of the provider’s Medicaid revenue), with those two codes combining to represent the bulk of the $15.1K total. Both Medicaid codes rank in the middle-to-lower statewide distribution (92134 at the 64th percentile; 67028 at the 30th percentile), indicating routine but not dominant in-state participation for these services.
Service mix includes both high-volume diagnostics and procedure-driven care: beyond injections, the provider bills substantial volumes for retinal imaging (92134 — Medicare $121.4K; Medicaid $8K) and performs isolated intravitreal procedures (67028 — Medicare $233.3K; Medicaid $7.1K). The presence of some surgical procedure codes (e.g., 67036, 67108, 67121) at lower volumes suggests occasional surgical retinal work in addition to a dominant outpatient injection/imaging practice.
The provider’s tenure adds contextual stability: the NPI was enumerated 2006-08-17 (~20 years ago), which indicates long-standing presence in the market and suggests these billing patterns reflect an established clinical model rather than a new or transient practice. Long tenure combined with high percentile rankings on several codes implies persistent, specialized retinal care activity over time.
Several statistical outliers highlight operational emphasis: 92134 is an extreme outlier on Medicare (99th percentile) indicating exceptionally high imaging volume, 99213 also appears as an extreme outlier (98th percentile) reflecting very high volumes of low-level E/M visits, and J0178 is notably above typical national volume (95th percentile). Together these outlier labels point to a practice that manages a large active retinal patient panel with frequent visits, imaging, and repeat injections.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
28 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 3,060 | $690 | $2.1M |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 16,560 | $30 | $480.2K |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 1,190 | $220 | $258.7K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 2,070 | $110 | $233.3K |
| J2778 | Injection, ranibizumab, 0.1 mg | 1,220 | $180 | $218K |
| J3490 | Unclassified drugs | 60 | $2,100 | $124.1K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 3,370 | $40 | $121.4K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 1,020 | $80 | $82.7K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 900 | $80 | $68.9K |
| Q5124 | Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | 310 | $180 | $53.4K |
Showing 1–10 of 28
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 28 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
28 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 14 | 230 | 560 | $690 | $693K |
| J2777 | 27 | 120 | 7,740 | $30 | $364.9K |
| Q5128 | 10 | 20 | 1,170 | $220 | $268.3K |
| J2778 | 11 | 70 | 510 | $180 | $131.6K |
| J2781 | 25 | 40 | 520 | $120 | $75.1K |
| Q5124 | 10 | 20 | 310 | $170 | $69.7K |
| 67028 | 16 | 300 | 400 | $100 | $65.9K |
| J3490 | 60 | 120 | 60 | $470 | $50.8K |
| 92014 | 560 | 2,220 | 160 | $100 | $29.3K |
| 67036 | 12 | 50 | 20 | $940 | $23.5K |
Showing 1–10 of 28
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 800 | $10 | $8K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 140 | $50 | $7.1K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 10 | $10 | $170 |
| 92226 | N/A | 30 | $1 | $90 |
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
4 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 1,345 | 1,460 | 310 | $60 | $88.1K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 183 | 260 | 420 | $70 | $65.6K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 264 | 730 | 370 | $20 | $30K |
| 92226 | N/A | 351 | 400 | 270 | $20 | $12.6K |
Other providers in the same ZIP code as Vincent Deramo, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| C And T Homecare Services LLC | NY | In Home Supportive Care Agency | $0 | $847.7M |
| North Shore-lij Medical PC | NY | Urology Physician | $0 | $388.1M |
| First Choice Home Care Inc | NY | Home Health Agency | $0 | $28M |
| Welllife Network Inc. | NY | Clinic/Center | $0 | $22M |
| Regioncare Inc. | NY | Home Infusion Agency | $40.1K | $9.4M |
| Philip Ferrone | NY | Ophthalmology Physician | $3.1M | $10.5K |
| Shahram Shamekh | NY | Internal Medicine Physician | $673.3K | $1.4M |
| Angela Azar | NY | Dermatology Physician | $104.5K | $1.5M |
| Alireza Shirvani | NY | Hospitalist Physician | $1.4M | $178K |
| Stephanie Buck-haskin | NY | Obstetrics & Gynecology Physician | $56.1K | $1.4M |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.